Real-world study shows Dara-RVD achieves high efficacy and manageable adverse events in high-risk multiple myeloma patients, suggesting new treatment approaches are needed.
Key Points
To evaluate the efficacy of Dara-RVd in newly diagnosed high-risk multiple myeloma patients in a real-world setting.
Inclusion of twelve high-risk NDMM patients receiving Dara-RVd induction therapy from 2024 to 2025.
MRD-adaptive strategy followed by autologous stem cell transplantation was employed based on post-ASCT MRD status.
Adverse events and clinical responses were assessed according to the International Myeloma Working Group criteria.
83% overall response rate with 6 patients achieving partial response and 2 achieving very good partial response.
7 out of 10 patients achieved MRD-negative status after induction therapy.
Notable adverse events included secondary immunodeficiency and respiratory tract infections in a proportion of patients.